AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS) patients, has met its primary objective. The ongoing study is currently recruiting participants and expects to finish in June 2017. “The positive outcome of this study in ALS is a significant milestone…
AB Science Reports Positive Interim Results in Phase 3 Trial of Masitinib as an ALS Therapy
In this ALS Association video watch specialists in ALS care explore the choices available for respiratory support. Learn more about ALS here: https://bit.ly/ALSNewsToday ALS News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is…
Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…
According to the Motor Neurone Disease Association, here are some common symptoms and effects of MND: Discomfort and pain: although they do not come from MND directly. Muscle cramps and spasms: which may be eased by changing positions. If you feel these changes are not enough, talk to your doctor. Stiff joints: some slow…
Leaders in the field of induced pluripotent stem cell (iPSC) – a technology that can help derive motor neurons from people who suffer from amyotrophic lateral sclerosis (ALS) – have published a cutting-edge review, identifying advances and challenges in ALS modeling ability and calling for the development and adoption of rigorous criteria…
7 ALS Headlines
1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on…
Graduate Rebecca Borg Talks About Her Research Project and the Difficulties of Earning Funds for ALS Research
In this cauchilab video, “Cyrielle Delmas meets graduate Rebecca Borg at her Dr. Cauchi’s lab at the University of Malta to talk about her research on ways to cure ALS/motor neuron disease.” Learn more about Borg’s research here: https://www.researchgate.net/profile/Rebecca_Borg2 Learn more about ALS here: https://bit.ly/ALSNewsToday…
ALS – Canadian Adult Stem Cell Research
https://www.youtube.com/watch?v=XJE8OxUn0d4 In this video by the Adaptive Canuck ALS Foundation, learn more about their work with families living with ALS and with adult stem cell research. Learn more about ALS here: https://bit.ly/ALSNewsToday…
13 ALS Facts You Should Know About
ALS, or amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. A-myo-trophic comes from the Greek language. “A” means no. “Myo” is referring to the muscle, and “Trophic” means nourishment –…
ALS.net has just announced the launch of “ALS Unfiltered,” a series of public sessions that will offer expert-led presentations and open conversations about amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), current research status, clinical trials, resources and other topics. The seminars will be held in several cities…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients